hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06262204, orgStudyIdInfo id: Hallux Shark Screw(R), briefTitle: Hallux Valgus Correction Using the Metal Screw or the Human Allogeneic Cortical Bone Screw (Shark Screw)., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-02-28, completionDateStruct date: 2026-02-28, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Orthopedic Hospital Vienna Speising, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare the treatment of Hallux Valgus using the conventional method (metal screw) with the new method (human allogeneic cortical bone screw (Shark Screw®) in adult patients with confirmed Hallux Valgus.The main questions it aims to answer are:Can the new method obtain comparable results as the conventional method in regard to union rate and time to union? Are the number of complications lower with the new method? Participants will be operated either with the metal screw or with the Shark Screw®. The assignment to the groups is randomized., conditionsModule conditions: Hallux Valgus, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: does get the information only after 2 years at the end of teh study, whoMasked: PARTICIPANT, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Hallux Valgus Treatment with Shark Screw®, interventions name: Hallux Valgus Treatment with metal screw, outcomesModule primaryOutcomes measure: clinical result of Hallux Valgus treatment, secondaryOutcomes measure: radiological (bony union)result of Hallux Valgus treatment, secondaryOutcomes measure: change in forefoot-American Orthopaedic Foot and Ankle Society (AOFAS), secondaryOutcomes measure: Hallux-Valgus angle (HVA) change, secondaryOutcomes measure: gait analysis, secondaryOutcomes measure: Intermetatarsal angle (IMA) change, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Abteilung für Kinderorthopädie und Fußchirurgie Orthopädisches Spital Speising, city: Vienna, zip: 1130, country: Austria, contacts name: Florian Wenzel-Schwarz, MD, role: CONTACT, phone: +43180182, phoneExt: 3081, email: florian.wenzel-schwarz@oss.at, contacts name: Florian Wenzel-Schwarz, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 48.20849, lon: 16.37208, hasResults: False
protocolSection identificationModule nctId: NCT06262191, orgStudyIdInfo id: 2137249, briefTitle: Testing an Adjustable Ankle Orthosis During Walking in Cerebral Palsy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Northern Arizona University, class: OTHER, descriptionModule briefSummary: This study seeks to determine how an adjustable stiffness ankle braces affects walking performance and biomechanics in cerebral palsy., conditionsModule conditions: Cerebral Palsy, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Differential and adjustable stiffness AFO (DAS-AFO), outcomesModule primaryOutcomes measure: Muscle activity, primaryOutcomes measure: Metabolic cost of transport, secondaryOutcomes measure: Pictorial Children's Effort Rating Table (PCERT), secondaryOutcomes measure: System Usability Score (SUS) questionnaire, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 35 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Northern Arizona University, status: RECRUITING, city: Flagstaff, state: Arizona, zip: 86011, country: United States, contacts name: Zach Lerner, PhD, role: CONTACT, phone: 928-523-1787, email: zachary.lerner@nau.edu, geoPoint lat: 35.19807, lon: -111.65127, hasResults: False
protocolSection identificationModule nctId: NCT06262165, orgStudyIdInfo id: RC23_0497, briefTitle: Evaluation of Liver Damage in Patients With Anorexia Nervosa by Blood Biomarker Analysis, acronym: BILAN, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-16, primaryCompletionDateStruct date: 2032-06-15, completionDateStruct date: 2032-12-15, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Nantes University Hospital, class: OTHER, descriptionModule briefSummary: The main goal of the BIocoLlection in Anorexia Nervosa-liver damage evaluation BILAN study the blood biomarkers associated with liver cytolysis., conditionsModule conditions: Anorexia Nervosa, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Patients with Anorexia Nervosa, outcomesModule primaryOutcomes measure: Identification of new blood biomarkers and hepatic cytolysis, eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 99 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nantes University Hospital, status: RECRUITING, city: Nantes, state: Loire-Atlantique, zip: 44093, country: France, contacts name: Sarra SMATI-GRANGEON, MCU-PH, role: CONTACT, phone: 33 2 53 48.27.01, email: sarra.grangeon@chu-nantes.fr, geoPoint lat: 47.21725, lon: -1.55336, hasResults: False
protocolSection identificationModule nctId: NCT06262152, orgStudyIdInfo id: 49187/2023, briefTitle: Sleep Profile of Patients With Septo-optic Dysplasia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-20, primaryCompletionDateStruct date: 2024-01-20, completionDateStruct date: 2025-05-20, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: IRCCS National Neurological Institute "C. Mondino" Foundation, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate sleep of patients with septo-optic dysplasia compared to patients with an isolated disorder of peripheral visual system and patients with corpus callosum agenesis since both visus defict and agenesis of corpus callosum might be present SOD but associated to other features / structural and functional anomalies.Included patients and their caregivers will be asked to compile standardize sleep questionnaires and a sleep screening through an interview will be scheduled. Patients will be asked to wear an actigraph on their non-dominant hand wrist for 7 days., conditionsModule conditions: Septo-Optic Dysplasia, conditions: Agenesis of Corpus Callosum, conditions: Blindness, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Actigraphy, blood and salivary sample, and sleep evaluation, outcomesModule primaryOutcomes measure: Sleep profile ( Sleep quality, sleep efficiency) of patients with SOD, secondaryOutcomes measure: melatonin profile of patients with SOD, secondaryOutcomes measure: Sleep EEG description of patients with SOD, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: IRCCS Casimiro Mondino Foundation, status: RECRUITING, city: Pavia, state: PV, zip: 27100, country: Italy, contacts name: Ludovica Pasca, MD, role: CONTACT, phone: 00393337201551, email: ludovica.pasca@mondino.it, contacts name: Valentina Franco, MD, role: CONTACT, geoPoint lat: 45.19205, lon: 9.15917, hasResults: False
protocolSection identificationModule nctId: NCT06262139, orgStudyIdInfo id: MT218-002, briefTitle: Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Molecular Theranostics LLC, class: INDUSTRY, collaborators name: Emory University, descriptionModule briefSummary: This phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for radical prostatectomy., conditionsModule conditions: MRI Scan, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SEQUENTIAL, interventionModelDescription: prostate cancer patients, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: MT218 injection, outcomesModule primaryOutcomes measure: Detection of aggressive prostate cancer (Gleason score 8 to 10) using peptide based MRI contrast agent (MT218) with comparing the previous clinical mpMRI using the clinical standard MRI contrast agent and PSMA-PET/CT, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Emory University, city: Atlanta, state: Georgia, zip: 30322, country: United States, geoPoint lat: 33.749, lon: -84.38798, hasResults: False
protocolSection identificationModule nctId: NCT06262126, orgStudyIdInfo id: 23-012673, briefTitle: Virtual Reality for Non-cardiac Chest Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-14, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The purpose of this study is to determine if virtual reality (VR) will improve symptoms in non-cardiac chest pain (NCCP)., conditionsModule conditions: Gastrointestinal Diseases, conditions: Chest Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Virtual Reality, outcomesModule primaryOutcomes measure: Measure changes in GERD symptoms using the GERDQ questionnare, primaryOutcomes measure: Measure changes in GERD quality of life using the GERD-HRQL questionnaire, primaryOutcomes measure: Measure changes in esophageal symptom specific anxiety using the EHAS questionnaire, primaryOutcomes measure: Measure changes in GI symptom severity using the PAGI-SYM questionnaire, primaryOutcomes measure: Measure changes in GI related patient assessment of quality of life using PAGI-QOL, secondaryOutcomes measure: Measure changes in anxiety and depression using the HADs scale, secondaryOutcomes measure: Measure changes in resilience using the brief resilience scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic Florida, status: RECRUITING, city: Jacksonville, state: Florida, zip: 32224, country: United States, contacts name: Wendi Lehman, role: CONTACT, phone: 904-953-8742, email: Lehman.Wendi@mayo.edu, geoPoint lat: 30.33218, lon: -81.65565, hasResults: False
protocolSection identificationModule nctId: NCT06262113, orgStudyIdInfo id: 2024P000392, secondaryIdInfos id: AD-2022C2-24790, type: OTHER_GRANT, domain: PCORI, briefTitle: A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-11, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-08, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, collaborators name: Patient-Centered Outcomes Research Institute, descriptionModule briefSummary: The goal of this fully decentralized, randomized controlled trial is to compare the efficacy of two educational interventions for individuals with Neurofibromatosis 1 (NF1). The primary objective of the study is to determine which intervention leads to higher rates of evidenced-based health screenings for NF1 patients in primary care settings.Adults with NF1 and parents/guardians of children with NF1 from across the U.S. who do not go to a specialized NF clinic and who have an upcoming annual wellness visits scheduled with a primary care provider (PCP) are eligible to enroll in the study., conditionsModule conditions: Neurofibromatosis 1, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 360, type: ESTIMATED, armsInterventionsModule interventions name: Letters about NF1 Care (Content Type 1), interventions name: Letters about NF1 Care (Content Type 2), outcomesModule primaryOutcomes measure: Receipt of Recommended NF1 Health Screenings, secondaryOutcomes measure: Patient Activation Measure®, secondaryOutcomes measure: Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Clinician and Group Survey Version 4.0 (Beta): Rating of the Visit, secondaryOutcomes measure: Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Clinician and Group Survey Version 4.0 (Beta): How Well Providers Communicate With Patients Subscale, secondaryOutcomes measure: Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Clinician and Group Survey Version 4.0 (Beta): Providers' Use of Information to Coordinate Patient Care Subscale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Massachusetts General Hospital, city: Boston, state: Massachusetts, zip: 02114, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06262100, orgStudyIdInfo id: EYL_23_01, briefTitle: Lubricating Effectiveness of Carragelose Eye Drops in Patients Affected by Mild to Moderate Dry Eye, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-15, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-12-15, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Marinomed Biotech AG, class: INDUSTRY, descriptionModule briefSummary: Patients suffering from dry eye syndrom will treat their eyes with Carragelose® eye drops three times a day for 28 days. Before, in the middle and at the end of the treament period patients will be exposed to adverse conditions to challenge dry eye symptoms. Patient will record their occular symptoms and ophthalmic examinations will be performed by an ophthalmologist. Differences between before and after treatment will be assessed., conditionsModule conditions: Dry Eye Syndromes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Carragelose, outcomesModule primaryOutcomes measure: Change in dry eye symptoms, secondaryOutcomes measure: Responder analysis, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IOBA,Ocular Surface Research Group, University of Valladolid, status: RECRUITING, city: Valladolid, zip: 47011, country: Spain, contacts name: Marta Balanco Vázquez, PhD, role: CONTACT, phone: C, email: mblancov@ioba.med.uva.es, contacts name: Margarita Calogne, PhD, role: CONTACT, phone: V, email: calogne@ioba.med.uva.es, geoPoint lat: 41.65518, lon: -4.72372, hasResults: False
protocolSection identificationModule nctId: NCT06262087, orgStudyIdInfo id: MU-CIRB 2023/044.2203, briefTitle: The Combined FIFA 11+ and Change of Direction Training, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Mahidol University, class: OTHER, descriptionModule briefSummary: The study has investigated the effects of adding change of direction (COD) training to the FIFA 11+ on lower extremity performance in soccer players. The investigators are interested in knee valgus angle during cutting which is typically suggested as a critical risk of anterior cruciate ligament injury. Peak knee valgus angle during cutting is expected to reduce immediately after adding COD training to the FIFA 11+., conditionsModule conditions: Rehabilitation, conditions: Physical Therapy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Change of direction training, interventions name: FIFA 11+ program, outcomesModule primaryOutcomes measure: Peak knee valgus angle, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: FFC league in Cambodia, status: RECRUITING, city: Phnom Penh, country: Cambodia, contacts name: Komsak Sinsurin, Ph.D., role: CONTACT, phone: +66 024415450, phoneExt: 20605, email: komsak.sin@mahidol.edu, contacts name: Chanteng Huoth, M.Sc., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 11.56245, lon: 104.91601, hasResults: False
protocolSection identificationModule nctId: NCT06262074, orgStudyIdInfo id: IEC-2418, briefTitle: Effect of Structured Training Program in Diabetic Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-08, primaryCompletionDateStruct date: 2024-02-08, completionDateStruct date: 2024-03-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Maharishi Markendeswar University (Deemed to be University), class: OTHER, descriptionModule briefSummary: Diabetic neuropathy, a challenging condition resulting from poorly managed type-1 or type-2 diabetes mellitus, often proves resistant to conventional medications when it comes to alleviating the associated symptoms. In such cases, implementing a well-organized exercise regimen has proven beneficial in mitigating diverse symptoms associated with the condition and enhancing the overall quality of life for affected individuals., conditionsModule conditions: Diabetic Peripheral Neuropathy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Structured Exercise Program, interventions name: Non structured exercise program, outcomesModule primaryOutcomes measure: Michigan neuropathy screening instrument (MNSI), primaryOutcomes measure: Biothesiometer, primaryOutcomes measure: NeuroQoL, secondaryOutcomes measure: NPRS, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MMIPR, status: RECRUITING, city: Ambala, state: Haryana, zip: 133207, country: India, contacts name: Subhashish Chatterjee, MPT(NEURO), role: CONTACT, phone: +918950037407, email: subhasishphysio@gmail.com, contacts name: Subhashish Chatterjee, MPT, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.36099, lon: 76.79782, hasResults: False
protocolSection identificationModule nctId: NCT06262048, orgStudyIdInfo id: PrePOURTS, briefTitle: Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial, acronym: PrePOURTS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-05-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Lawson Health Research Institute, class: OTHER, descriptionModule briefSummary: The objectives of this study are to determine the efficacy of tamsulosin compared to placebo in reducing post-operative urinary retention and improving other clinical outcomes in people undergoing pulmonary surgery., conditionsModule conditions: Urinary Retention Postoperative, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: single centre, double blind randomized controlled trial, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Tamsulosin Hydrochloride, interventions name: Placebo, outcomesModule primaryOutcomes measure: Rate of post operative urinary retention, secondaryOutcomes measure: Rate of Straight Catheterizations, secondaryOutcomes measure: Rate of Indwelling Catheterizations, secondaryOutcomes measure: Time to first catheterization, secondaryOutcomes measure: Treatment Related Adverse Events, secondaryOutcomes measure: Catheter related complications, secondaryOutcomes measure: Length of stay, eligibilityModule sex: ALL, minimumAge: 40 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: London Health Sciences Centre, city: London, state: Ontario, zip: N6A 5W9, country: Canada, geoPoint lat: 42.98339, lon: -81.23304, hasResults: False